Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 9/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.42 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.42 |
| ▸ | USP7 | Q93009 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27779432 | 0.85 | DYRK1A (0.49) | DYRK1AKCNH2SCN10ANPY5RCLK2 | |
| SCHEMBL16694014 | 0.85 | KCNH2 (0.51) | DYRK1AKCNH2SCN10ANPY5RCLK2 | |
| SCHEMBL12277379 | 0.85 | DYRK1A (0.46) | DYRK1AKCNH2SCN10ANPY5RHSD11B1 | |
| SCHEMBL12277808 | 0.85 | DYRK1A (0.46) | DYRK1AKCNH2SCN10ANPY5RHSD11B1 | |
| SCHEMBL23571873 | 0.84 | F2 (0.49) | DYRK1A | |
| SCHEMBL27779024 | 0.84 | DYRK1A (0.48) | DYRK1AKCNH2SCN10ANPY5RCLK2 | |
| SCHEMBL5362756 | 0.83 | DYRK1A (0.56) | DYRK1A | |
| SCHEMBL14960652 | 0.81 | KDM4E (0.46) | KCNH2SCN10AHSD11B1 | |
| SCHEMBL14412223 | 0.81 | NMT1 (0.52) | — | |
| SCHEMBL12832618 | 0.79 | NPC1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-05-07 | — | — | US | disclosed |
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8445503-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | DYRK1A 309/4885KCNH2 2013/4885SCN10A 4161/4885 |
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | DYRK1A 320/4885KCNH2 1968/4885SCN10A 4144/4885 |
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | DYRK1A 320/4885KCNH2 1968/4885SCN10A 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.